GILD - Gilead's Trodelvy misses primary endpoint in phase 3 bladder cancer trial
2024-05-30 17:06:32 ET
More on Gilead Sciences
- Gilead Sciences: Seriously Undervalued At Peak Pessimism
- Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish
- Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows
- Gilead partnering with Cartography Biosciences to discover cancer therapies
- Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo